T2 Biosystems announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its first contract option valued at $10.5M. The first option was exercised under the multi-year contract between BARDA and T2 Biosystems, valued at up to $69M if all options are exercised, following the Company's successful completion of the base option to further advance the development of the following products: A direct-from-blood panel to detect biothreat pathogens such as B. anthracis, F.tularensis, Y. pestis, Burkholderia spp., and R. prowazekii; A direct-from-blood panel to cover up to 99% of all bloodstream infections by means of greater than or equal to36 reported results, including pan-Gram positive and pan-Gram negative results, in addition to resistance genes associated with the bloodborne antibiotic resistant threats identified by the Centers for Disease Control and Prevention; A next-generation high-throughput instrument. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00053.
Read more at: